Pharmacogenetic considerations in the treatment of gout

Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea

(2015) Dong-Jin Park et al.   ARTHRITIS CARE & RESEARCH

The global burden of gout: estimates from the Global Burden of Disease 2010 study

(2014) Emma Smith et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

(2014) M V Relling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Uricosuric drugs

(2014) Mary H. Bach et al.   CURRENT OPINION IN RHEUMATOLOGY

Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01

(2014) J. Yun et al.   JOURNAL OF IMMUNOLOGY

PharmGKB summary

(2014) Ellen M. McDonagh et al.   Pharmacogenetics and Genomics

Methaemoglobinaemia and haemolysis following pegloticase infusion for refractory gout in a patient with a falsely negative glucose-6-phosphate dehydrogenase deficiency result

(2014) Laura Geraldino-Pardilla et al.   RHEUMATOLOGY

Impaired response or insufficient dosage?—Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout

(2014) Lisa K. Stamp et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

HLA-DR9 and DR14 Are Associated with the Allopurinol-Induced Hypersensitivity in Hematologic Malignancy

(2014) Jae-Woo Jung et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

HLA-B*58:01is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population

(2013) M. Gonçalo et al.   BRITISH JOURNAL OF DERMATOLOGY

Pharmacogenetics of Allopurinol-Making an Old Drug Safer

(2013) May P. S. Lam et al.   JOURNAL OF CLINICAL PHARMACOLOGY

HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population

(2013) Hiroyuki Niihara et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function

(2013) Kim Hughes et al.   KIDNEY INTERNATIONAL

PharmGKB summary

(2013) Ellen M. McDonagh et al.   Pharmacogenetics and Genomics

The Association of Four Common Polymorphisms from Four Candidate Genes (COX-1, COX-2, ITGA2B, ITGA2) with Aspirin Insensitivity: A Meta-Analysis

(2013) Zhiyuan Weng et al.   PLoS One

Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts

(2013) T. M. Palmer et al.   BMJ-British Medical Journal

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

(2012) Naomi Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

(2012) Lisa K. Stamp et al.   ARTHRITIS AND RHEUMATISM

Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes

(2012) Kaoru Kobayashi et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong

(2012) M.L.S. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

(2012) M S Hershfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genome-wide association analyses identify 18 new loci associated with serum urate concentrations

(2012) Anna Köttgen et al.   NATURE GENETICS

PharmGKB summary

(2012) Ellen M. McDonagh et al.   Pharmacogenetics and Genomics

HLA-B*58:01allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese

(2012) Zhi-hao Cao et al.   PHARMACOGENOMICS

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

(2012) Dinesh Khanna et al.   ARTHRITIS CARE & RESEARCH

Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies

(2011) Naohiko Anzai et al.   Clinical and Experimental Nephrology

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

(2011)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe

(2011) Emmanuelle Génin et al.   Orphanet Journal of Rare Diseases

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans

(2011) Hye-Ryun Kang et al.   Pharmacogenetics and Genomics

A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients

(2011) M Tohkin et al.   PHARMACOGENOMICS JOURNAL

Association between ABCB1 (MDR1) Gene 3435 C>T Polymorphism and Colchicine Unresponsiveness of FMF Patients

(2011) Filiz Ozen et al.   RENAL FAILURE

Does genetic variability in aldehyde oxidase and molybdenum cofactor sulfurase predict nonresponse to allopurinol?

(2010) R. L. Roberts et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors

(2010) Qiong Yang et al.   Circulation-Cardiovascular Genetics

CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin

(2010) N Carbonell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Benzbromarone Pharmacokinetics and Pharmacodynamics in Différent Cytochrome P450 2C9 Genotypes

(2010) Shinya Uchida et al.   Drug Metabolism and Pharmacokinetics

PharmGKB summary

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

Very important pharmacogene summary

(2010) Laura M. Hodges et al.   Pharmacogenetics and Genomics

Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease

(2009) M. A. SMITH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout

(2009) Ming-Han H Lee et al.   DRUG SAFETY

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

(2009) Wichittra Tassaneeyakul et al.   Pharmacogenetics and Genomics

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

(2009) O. M. Woodward et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Polymorphisms of human cytochrome P450 2C9 and the functional relevance

(2009) Shu-Feng Zhou et al.   TOXICOLOGY

Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations

(2009) Melanie Kolz et al.   PLoS Genetics

Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT 1) in Hypertensive Patients

(2008) T. Hamada et al.   AMERICAN JOURNAL OF HYPERTENSION

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

(2008) Abbas Dehghan et al.   LANCET

Glucose-6-phosphate dehydrogenase deficiency

(2008) MD Cappellini et al.   LANCET

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

(2008) Veronique Vitart et al.   NATURE GENETICS

SLC2A9 influences uric acid concentrations with pronounced sex-specific effects

(2008) Angela Döring et al.   NATURE GENETICS

A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

(2008) Christine Lonjou et al.   Pharmacogenetics and Genomics

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis

(2008) Nahoko Kaniwa et al.   PHARMACOGENOMICS

SLC2A9 Is a High-Capacity Urate Transporter in Humans

(2008) Mark J Caulfield et al.   PLOS MEDICINE